



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

17 April 2017

DEPARTMENT MEMORANDUM

No. 2017 – 0161

TO : DOH – ARMM SECRETARY, ALL DIRECTORS OF DOH REGIONAL OFFICES, CHIEFS OF MEDICAL CENTERS, HOSPITALS, SANITARIA, EXECUTIVE DIRECTORS OF SPECIALTY HOSPITALS AND OTHER CONCERNED

SUBJECT : Clarification of the Quadrivalent Human Papillomavirus Vaccine (HPV) (Types 6, 11, 16 and 18) in the Drug Price Reference Index (DPR)

This is to clarify the specification of the Quadrivalent Human Papillomavirus Vaccine (HPV) (Types 6, 11, 16 and 18) stipulated in the Drug Price Reference Index (DPR).

The procurement price of the Department of Health (DOH) for the Quadrivalent HPV Vaccine last 2015 was used as basis for setting the 2016 reference price for the Quadrivalent HPV Vaccine 0.5 mL Pre-filled Syringe (PFS). Recognizing that the sole manufacturer of the said product is providing exclusively in Vial forms to the DOH with a lower price due to bulk procurement, the pharmaceutical form of the latter in the latest DPR booklet shall be reflected as **Vial** rather than PFS.

Furthermore, the setting of the Approved Budget of Contract (ABC) for the Quadrivalent HPV 0.5 mL PFS shall depend on the procuring entity's discretion while the DOH shall remain to comply with the reference price for the procurement of the Vial form of the said molecule.

Dissemination of the information to all concerned is required.

By Authority of the Secretary of Health:

EDTAYAG
ENRIQUE A. TAYAG, MD, PHSAE, FPSMID, CESO III
OIC - Assistant Secretary of Health
Office for Policy and Health Systems